Strides Shasun Limited
Strides House, Bannerghatta Road,
Bangalore – 560076.

Press Release
July 2, 2018

Strides Shasun receives USFDA Tentative Approval for Milnacipran Hydrochloride Tablets

Product approval under the para IV route

Bangalore, July 2, 2018 Strides Shasun Limited today announced that its wholly owned subsidiary Strides Pharma Global Pte. Ltd. has received tentative approval for its Para IV filing of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg from the United States Food & Drug Administration (US FDA). Milnacipran Hydrochloride Tablet is a generic version of Savella® Tablets of Allergan Sales, LLC (Allergan).

As per IQVIA MAT data, the US market for Milnacipran Hydrochloride Tablets is approximately USD 145 Million. The product will be manufactured at the Company’s Oral dosage facility at Puducherry and will be marketed by Strides Pharma Inc. in the US Market. Further updates on commercialization will be provided on receiving the final approval for the product.

The company has 75 cumulative ANDA filings with USFDA of which 51 ANDAs have been approved as of date and 24 are pending approval.

About Milnacipran Hydrochloride Tablets

Milnacipran Hydrochloride Tablet is used to treat pain caused by a condition called fibromyalgia that affects the muscles, tendons, ligaments, and supporting tissues. This medication is a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by helping to restore the balance of certain natural substances in the brain (neurotransmitters).

About Strides Shasun

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is global pharmaceutical Company headquartered in Bangalore. The Company has two business verticals, viz., Regulated Markets and Emerging Markets.
The Company has global manufacturing footprint with 7 manufacturing facilities spread across three continents including 5 US FDA approved facilities and 2 facilities for the emerging markets. The Company has strong R&D infrastructure in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company’s website at www.stridesarco.com

For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>PR Consultancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Badree Komandur, Executive Director</td>
<td>Fortuna PR</td>
</tr>
<tr>
<td>+91 80 6784 0747</td>
<td>K Srinivas Reddy: +91 9000527213</td>
</tr>
<tr>
<td>Investors:</td>
<td><a href="mailto:srinivas@fortunapr.com">srinivas@fortunapr.com</a></td>
</tr>
<tr>
<td>Kannan. N: +91 98450 54745</td>
<td>K Priya: +91 9535425418</td>
</tr>
<tr>
<td>Vikesh Kumar: +91 80 6784 0827</td>
<td><a href="mailto:priya@fortunapr.com">priya@fortunapr.com</a></td>
</tr>
<tr>
<td>Sandeep Baid: +91 80 6784 0791</td>
<td></td>
</tr>
</tbody>
</table>

Strides Shasun Limited
CIN : L24230MH1990PLC057062
Email: investors@stridesshasun.com